Suvarna Garge (Editor)

Benitec Biopharma Ltd

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Type
  
Biotechnology

Industry
  
RNA interference

Revenue
  
1.374 million USD (2014)

Number of employees
  
7 (2013)

Traded as
  
ASX: BLT

Profit
  
($4,801,752) (2013)

Founded
  
1997


Key people
  
Peter Francis (Chairman) Greg West (CEO) Bryan Dulhunty (CFO) Michael Graham (Founding Scientist & Head of Discovery)

Products
  
Gene silencing, Gene expression, RNA interference (ddRNAi)

Stock price
  
BLT (ASX) A$ 0.19 0.00 (0.00%)3 Mar, 3:08 PM GMT+11 - Disclaimer

Headquarters
  
New South Wales, Australia

Benitec Biopharma Ltd ASX: BLT is an Australian biotechnology company founded in 1997. It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference (ddRNAi) technology.

Contents

RNA interference (RNAi) was awarded the Nobel Prize in Physiology or Medicine in 2006. The Commonwealth Scientific and Industrial Research Organisation (CSIRO) has researched RNAi extensively, developing the small hairpin RNA concept employed in ddRNAi. Benitec Biopharma has an exclusive license to this ddRNAi technology in human therapeutic uses and research.

Partnerships and Collaborations

Benitec Biopharma and its subsidiary Tacere Therapeutics has partnerships with:

  • For laboratory reagents: Promega, Chemicon (Millipore Corporation), Integrated DNA Technologies, Genscript, Ambion Inc (Applied Biosystems), Origene Technologies Inc, Sigma Aldrich
  • For transgenic animals: Artemis Pharmaceutical GmbH, GenOway
  • For commercial research use: Merck & Co, Pfizer
  • Licensing agreements: Calimmune (US), Carnegie Institution for Science (University of Massachusetts, US), Children's Cancer Institute Australia for Medical Research (CCIA) (University of New South Wales, Australia), Biomics Biotechnologies (China), Genable Technologies (Ireland), Stanford University (US), Royal Holloway (University of London, UK), Revivicor (US), Regen BioPharma (a subsidiary of Bio-Matrix, US), and UniQure BV (the Netherlands).

    • Research and Development

    Benitec Biopharma and its partners and licensees are researching ddRNAi in the following fields:

  • Hepatitis C (under development by subsidiary Tacere Therapeutics; Phase I/II trial; NCT01899092)
  • Hepatitis B (under development with partner Biomics Biotechnologies))
  • HIV (under development by Calimmune; Phase I/II trial; NCT01899092)
  • Neuropathic pain
  • Drug-resistant non-small cell lung cancer (under development by Children's Cancer Institute Australia)
  • Oculopharyngeal muscular dystrophy (OPMD)
  • Autosomal dominant retinitis pigmentosa (under development by partner Genable Technologies)
  • Wet age-related macular degeneration (under development with subsidiary Tacere Therapeutics)
  • Huntington's disease (under development by partner uniQure).

    • Intellectual Property

    Benitec Biopharma holds an intellectual property portfolio for ddRNAi technology in humans and mammals, currently totalling 104 patents in 20 jurisdictions.

    References

    Benitec Biopharma Ltd Wikipedia
    (Text) CC BY-SA